| Expression pattern: |
DN |
| Associated gene: |
PTEN |
| Associated microRNA: |
miR-1269b |
| Biological function: |
inhibits proliferation; induces G1 phase arrest; suppresses AML progression |
| Molecular mechanism: |
Acts as a competitive endogenous RNA (ceRNA) by sponging miR-1269b to regulate PTEN expression |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (inhibits); cell cycle (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Back-Splice Junction PCR / divergent primers PCR; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Clinical Sample Validation; ROC Analysis; Western Blot; Microarray |
| Clinical significance: |
Lower hsa_circ_0001776 in AML patients vs controls with diagnostic value (ROC AUC=0.9091); suggested as a diagnostic biomarker and therapeutic target |
| Description: |
hsa_circ_0001776 is down-regulated in AML peripheral blood and inhibits AML cell proliferation by inducing G0/G1 arrest. Mechanistically, it functions as a ceRNA that sponges miR-1269b, thereby relieving repression of PTEN and suppressing AML progression. It shows diagnostic potential based on ROC analysis in a small clinical cohort. |
| Confidence score: |
0.8357 |